Repro India Limited disclosed its unaudited standalone and consolidated financial results for Q2 FY27 ending September 30, 2026, pursuant to Regulation 47 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Financial Performance (Standalone - in ₹ lakhs)

Quarter ended September 30, 2026 (Unaudited):

  • Total Income from Operations: ₹16,157
  • Net Profit before tax (before exceptional items): ₹3,252
  • Net Profit before tax (after exceptional items): ₹3,252
  • Net Profit after tax: ₹2,169
  • Total Comprehensive Income: ₹3,141
  • Equity Share Capital: ₹860
  • Basic EPS: ₹25.22
  • Diluted EPS: ₹25.22

Half-year ended September 30, 2026 (Unaudited):

  • Total Income from Operations: ₹25,657
  • Net Profit before tax: ₹3,099
  • Net Profit after tax: ₹2,046
  • Total Comprehensive Income: ₹1,854
  • Basic EPS: ₹23.79
  • Diluted EPS: ₹23.79

Comparative Figures (Quarter ended September 30, 2025):

  • Total Income from Operations: ₹11,471
  • Net Profit before tax (before exceptional items): ₹1,554
  • Net Profit before tax (after exceptional items): ₹1,704
  • Net Profit after tax: ₹1,456
  • Total Comprehensive Income: (₹3,122)
  • Basic EPS: ₹16.93
  • Diluted EPS: ₹16.93

Year ended March 31, 2026 (Audited):

  • Total Income from Operations: ₹42,946
  • Net Profit before tax (before exceptional items): ₹3,861
  • Net Profit before tax (after exceptional items): ₹9,025
  • Net Profit after tax: ₹4,803
  • Total Comprehensive Income: ₹3,858
  • Basic EPS: ₹55.85
  • Diluted EPS: ₹55.85

Dividend Declaration

The Board declared an interim dividend of ₹26 per equity share (par value ₹10 each) for the quarter ended September 30, 2026. The record date is November 3, 2026, and payment will be made on November 11, 2026. The interim dividend declared in the previous year was ₹23 per equity share.

Employee Stock Grants

The Board, based on recommendations of the Nomination and Remuneration Committee, approved the grant of 9,640 Restricted Stock Units (RSUs) under the 2015 Incentive Compensation Plan to eligible employees. The grants will vest equally over three years, effective November 1, 2026, with exercise price equal to the par value of the share.

Audit and Compliance Notes

The statutory auditors, Deloitte Haskins & Sells LLP, have expressed an unmodified audit opinion on the financial statements. The financial results were published in Business Standard (English - All Editions) and Aapla Mahanagar (Marathi - Mumbai Edition) on October 24, 2026, as required by Regulation 47.

Additional Information

The document also contains financial results snippets from other companies:

  • Infosys Limited: Q2 FY27 consolidated revenue of ₹49,244 crore, profit for the period of ₹7,838 crore, basic EPS of ₹19.32
  • Dr. Reddy's Laboratories Limited: Mention of unaudited standalone and consolidated financial results for quarter and half-year ended September 30, 2026
  • Various municipal tender notices from Brihanmumbai Municipal Corporation and MHADA for infrastructure projects

The complete financial results are available on the company's website at www.reproindialtd.com and stock exchange websites.